Vilon
LongevityKhavinson dipeptide / researchExperimental
Lys-Glu dipeptide (Vilon) from the Khavinson series, studied for immune and geroprotective claims. Not FDA-approved.
For research use only.
Key Facts
- CAS
- 37908-74-6
- Molecular Weight (MW)
- 275.30 g/mol
- Half-life
- Not established in humans
- Unit
- mcg
- Administration Route
- —
- Frequency
- —
- Last updated
- 8/23/2026
- Targets
- Immune cells (proposed)
Overview
Lys-Glu dipeptide (Vilon) from the Khavinson series, studied for immune and geroprotective claims. Not FDA-approved.
Protocol
- Dosage Range
- Not established for FDA-approved use
- Frequency
- —
- Cycle
- —
- Administration Route
- —
- Reconstitution Guide
- —
Science
Mechanism of Action
Reported to modulate lymphocyte proliferation and geroprotective markers in Russian literature.
Targets
Immune cells (proposed)
Studies
- Vilon / Lys-Glu literature— Journal/year not available
Benefits
Immune-aging research category
Potential Side Effects
- Not well characterized
References
- PMID 15587334External link · Year —